| Filed On | Filing |
|---|---|
| 06 Oct 2026 |
8-K: Results of Operations and Financial Condition
In connection with its acquisition of Alesta Therapeutics B.V. (Alesta), a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid), which was completed on August 31, 2026, BioMarin Pharmaceutical In... |
| 01 Oct 2026 |
Form 4: Friberg Gregory R, EVP, Chief R&D Officer
Gave up 4,086 shares to cover exercise price or tax ($245K) |
| 30 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
On September 24, 2026, BioMarin Pharmaceutical Inc. (BioMarin) entered into a Settlement and License Agreement (the Agreement) with Ascendis Pharma A/S (Ascendis). |
| 15 Sep 2026 |
8-K: Other Events
On September 15, 2026, BioMarin Pharmaceutical Inc. (BioMarin) announced its decision to discontinue development of VOXZOGO for children with Noonan syndrome. BioMarin made this decision after assessing a number of factors, including the... |
| 14 Sep 2026 |
Form 4: Plenge Robert M, Director
Received 6,140 shares as a grant or award |
| 14 Sep 2026 |
Form 3: Plenge Robert M, Director
No securities owned |
| 14 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 10, 2026, the Board of Directors (the Board) of BioMarin Pharmaceutical Inc. (the Company) increased the size of the Board from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., to the Board, to be effective Se... |
| 03 Sep 2026 |
Form 4: Davis George Eric, EVP, Chief Legal Officer
Sold 17,557 shares ($1.16M) |
| 02 Sep 2026 | 144 |
| 01 Sep 2026 | 8-K: Other Events |
| 31 Aug 2026 | 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure |
| 18 Aug 2026 | 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure |
| 06 Aug 2026 | S-8 |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 13 Jul 2026 |
8-K/A: Other Events
To the Stockholders and the Board of Directors of Amicus Therapeutics, Inc. |
| 04 Jun 2026 |
Form 4: Countouriotis Athena, Director
Received 7,490 shares as a grant or award |
| 04 Jun 2026 |
Form 4: Walbert Timothy P, Director
Received 7,490 shares as a grant or award |
| 04 Jun 2026 |
Form 4: Ho Maykin, Director
Received 7,490 shares as a grant or award |
| 04 Jun 2026 |
Form 4: Hombach Robert J., Director
Received 7,490 shares as a grant or award |
Loading...
